Latest filings (excl ownership)
15-12G
Securities registration termination
18 Oct 23
8-K
Bankruptcy or Receivership
20 Sep 23
8-K
Other Events
22 Aug 23
8-K
Other Events
21 Jul 23
8-K
Other Events
12 Jul 23
8-K
Departure of Directors or Certain Officers
7 Jul 23
8-K
Other Events
27 Jun 23
8-K
Entry into a Material Definitive Agreement
26 May 23
25-NSE
Exchange delisting
2 May 23
8-K
Bankruptcy or Receivership
13 Apr 23
8-K
PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets
12 Apr 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10 Apr 23
8-K
Departure of Directors or Certain Officers
8 Mar 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Feb 23
8-K
Departure of Directors or Certain Officers
20 Jan 23
8-K
PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update
10 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Oct 22
DEFA14A
Additional proxy soliciting materials
29 Sep 22
DEF 14A
Definitive proxy
29 Sep 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
8-K
PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update
12 Aug 22
8-K
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update
13 May 22
10-Q
2022 Q1
Quarterly report
13 May 22
10-K/A
2021 FY
Annual report (amended)
29 Apr 22
8-K
Amendments to Articles of Incorporation or Bylaws
21 Apr 22
8-K
Regulation FD Disclosure
15 Mar 22
10-K
2021 FY
Annual report
11 Mar 22
8-K
PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
11 Mar 22
S-8
Registration of securities for employees
22 Nov 21
8-K
PLx Pharma Inc. Reports Third Quarter 2021 Results and Provides Business Update
12 Nov 21
10-Q
2021 Q3
Quarterly report
12 Nov 21
DEF 14A
Definitive proxy
5 Oct 21
8-K
Regulation FD Disclosure
21 Sep 21
EFFECT
Notice of effectiveness
18 Aug 21
CORRESP
Correspondence with SEC
13 Aug 21
UPLOAD
Letter from SEC
13 Aug 21
8-K
Entry into a Material Definitive Agreement
6 Aug 21
S-3
Shelf registration
6 Aug 21
10-Q
2021 Q2
Quarterly report
6 Aug 21
Latest ownership filings
SC 13G
Park West Asset Management LLC
6 Apr 23
SC 13G/A
MSD Partners, L.P.
14 Feb 23
4
Natasha Giordano
16 Mar 22
4
Rita M O'Connor
16 Mar 22
4
Michael J Valentino
24 Feb 22
4
Rita M O'Connor
24 Feb 22
4
JOHN HADDEN
24 Feb 22
4
Natasha Giordano
24 Feb 22
4
Robert Casale
24 Feb 22
4
KIRK K CALHOUN
24 Feb 22
4
Gary S. Balkema
24 Feb 22
SC 13G/A
WHITE ROCK CAPITAL MANAGEMENT LP
16 Feb 22
SC 13G/A
Rosalind Advisors, Inc.
14 Feb 22
SC 13G/A
Level One Partners, LLC
11 Feb 22
4
Rita M O'Connor
11 Aug 21
4
Natasha Giordano
11 Aug 21
4
Michael J Valentino
15 Jun 21
SC 13D/A
Park West Asset Management LLC
11 Jun 21
SC 13G
Level One Partners, LLC
16 Mar 21
3
Robert D. Hardie
16 Mar 21
4
Michael J Valentino
9 Mar 21
SC 13G/A
Rosalind Advisors, Inc.
22 Jan 21
SC 13G
Rosalind Advisors, Inc.
18 Dec 20
SC 13G
WHITE ROCK CAPITAL MANAGEMENT LP
16 Dec 20
4
JOHN HADDEN
15 Dec 20
4
JOHN HADDEN
25 Nov 20
4
Michael J Valentino
20 Nov 20
4
Rita M O'Connor
20 Nov 20
4
JOHN HADDEN
20 Nov 20
4
Natasha Giordano
20 Nov 20
4
Robert Casale
20 Nov 20
4
KIRK K CALHOUN
20 Nov 20
4
Gary S. Balkema
20 Nov 20
4
Rita M O'Connor
3 Sep 20
4
Rita M O'Connor
24 Aug 20
SC 13G
MSD Partners, L.P.
26 May 20
SC 13D/A
Park West Asset Management LLC
20 May 20
4
Change in insider ownership
19 May 20
4
Michael J Valentino
24 Mar 20
4
Rita M O'Connor
24 Mar 20